恩替卡韦联合心肝宝胶囊治疗慢性乙型肝炎肝硬化的疗效观察

Clinical efficacy of entecavir combined with Xinganbao capsules in treatment of liver cirrhosis among patients with chronic hepatitis B

目的观察恩替卡韦联合心肝宝治疗慢性乙型肝炎肝硬化的临床疗效。方法将本院2010年5月-2013年10月收治的60例慢性乙型肝炎肝硬化患者随机分为2组,治疗组(30例)给予恩替卡韦联合心肝宝胶囊治疗,对照组(30例)只给与恩替卡韦治疗,疗程均为6个月。观察2组治疗前后肝功能、血清纤维化指标和肝、脾影像学等项目。计量资料组间比较采用t检验,计数资料组间比较采用χ2检验。结果治疗组ALT、AST与对照组相比差异有统计学意义(P<0.05),血清纤维化指标,肝、脾影像学检查有显著改善(P<0.01)。结论恩替卡韦联合心肝宝治疗慢性乙型肝炎肝硬化,具有改善肝功能,减轻肝组织炎症;抗肝纤维化,降低门静脉压力和缩脾作用。

Objective To observe the clinical efficacy of entecavir combined with Xinganbao capsules in the treatment of liver cirrhosis among patients with chronic hepatitis B （CHB）. Methods Sixty CHB patients with liver cirrhosis were randomly divided into two groups ： treatment group （n = 30） given entecavir combined with Xinganbao capsules and control group （n = 30） given entecavir alone. The course of treatment was 6 months. The treatment outcomes were evaluated based on liver function, serum fibrosis markers, and imaging findings of the liver and spleen. Comparison of continuous data between groups was made by t test, while comparison of categorical data was made by chi - square test. Results After treatment, the treatment group had significantly lower serum levels of alanine aminotransferase and aspartate aminotransferase （P 〈0.05 ）, significantly reduced serum fibrosis markers （P 〈 0.01 ）, and significantly improved imaging findings of the liver and spleen （P 〈 0. 01 ）, as compared with the control group. Conclusion Entecavir combined with Xinganbao capsules can improve liver function, reduce hepatic inflammation and fibrosis, and decrease portal pressure and spleen thickness in the treatment of liver cirrhosis among CHB patients.